4888 — Stella Pharma Income Statement
0.000.00%
Last trade - 00:00- ¥12bn
- ¥11bn
- ¥269m
Annual income statement for Stella Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 206 | 100 | 229 | 269 |
| Cost of Revenue | |||||
| Gross Profit | — | 182 | 84.9 | 207 | 217 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 951 | 887 | 842 | 1,036 | 1,031 |
| Operating Profit | -951 | -681 | -742 | -807 | -761 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -959 | -656 | -764 | -776 | -761 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -962 | -659 | -768 | -779 | -764 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -962 | -659 | -768 | -779 | -764 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -962 | -659 | -768 | -779 | -764 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -35 | -23.9 | -27.3 | -27 | -24.6 |
| Dividends per Share |